Synergistic interactions of etoposide and interleukin-1 alpha are not due to DNA damage in human melanoma cells

Biochim Biophys Acta. 1993 Jan 22;1180(3):231-5. doi: 10.1016/0925-4439(93)90043-z.

Abstract

Several possible mechanisms of the synergistic interactions of IL-1 alpha and VP-16 against A375-C6 human melanoma cells were investigated. Studies indicate that IL-1 alpha did not increase topoisomerase II-dependent VP-16-mediated DNA damage, nor did IL-1 alpha inhibit the repair of VP-16-induced DNA damage in these cells. Furthermore, IL-1 alpha by itself or in combination with VP-16 did not cause significant fragmentation of cellular DNA into oligomers, indicating programmed cell death (apoptosis) was not involved in the mechanism of synergy. In contrast, an IL-1-specific receptor antagonist significantly decreased IL-1 alpha toxicity toward the melanoma cells and nearly eliminated the synergistic interactions of IL-1 alpha with VP-16. These results strongly indicate that synergism of IL-1 alpha with VP-16 was dependent upon an IL-1-receptor-mediated processes. DNA-strand breakage was unlikely to be a primary intracellular target for IL-1 alpha cytotoxicity and synergism with VP-16.

MeSH terms

  • Cytotoxins / metabolism
  • Cytotoxins / toxicity
  • DNA / drug effects
  • DNA Damage*
  • DNA Repair / drug effects
  • Drug Synergism
  • Etoposide / metabolism
  • Etoposide / toxicity*
  • Humans
  • Interleukin-1 / metabolism
  • Interleukin-1 / toxicity*
  • Melanoma
  • Receptors, Interleukin-1 / metabolism
  • Tumor Cells, Cultured

Substances

  • Cytotoxins
  • Interleukin-1
  • Receptors, Interleukin-1
  • Etoposide
  • DNA